Comparison of Prolonged Exposure vs Cognitive Processing Therapy for Treatment of Posttraumatic Stress Disorder Among US Veterans: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Importance: Posttraumatic stress disorder (PTSD) is a prevalent and serious mental health problem. Although there are effective psychotherapies for PTSD, there is little information about their comparative effectiveness. Objective: To compare the effectiveness of prolonged exposure (PE) vs cognitive processing therapy (CPT) for treating PTSD in veterans. Design, Setting, and Participants: This randomized clinical trial assessed the comparative effectiveness of PE vs CPT among veterans with military-related PTSD recruited from outpatient mental health clinics at 17 Department of Veterans Affairs medical centers across the US from October 31, 2014, to February 1, 2018, with follow-up through February 1, 2019. The primary outcome was assessed using centralized masking. Tested hypotheses were prespecified before trial initiation. Data were analyzed from October 5, 2020, to May 5, 2021. Interventions: Participants were randomized to 1 of 2 individual cognitive-behavioral therapies, PE or CPT, delivered according to a flexible protocol of 10 to 14 sessions. Main Outcomes and Measures: The primary outcome was change in PTSD symptom severity on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) from before treatment to the mean after treatment across posttreatment and 3- and 6-month follow-ups. Secondary outcomes included other symptoms, functioning, and quality of life. Results: Analyses were based on all 916 randomized participants (730 [79.7%] men and 186 [20.3%] women; mean [range] age 45.2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.9 [95% CI, 39.1-40.7] points) and 461 participants randomized to CPT (mean CAPS-5 score at baseline, 40.3 [95% CI, 39.5-41.1] points). PTSD severity on the CAPS-5 improved substantially in both PE (standardized mean difference [SMD], 0.99 [95% CI, 0.89-1.08]) and CPT (SMD, 0.71 [95% CI, 0.61-0.80]) groups from before to after treatment. Mean improvement was greater in PE than CPT (least square mean, 2.42 [95% CI, 0.53-4.31]; P = .01), but the difference was not clinically significant (SMD, 0.17). Results for self-reported PTSD symptoms were comparable with CAPS-5 findings. The PE group had higher odds of response (odds ratio [OR], 1.32 [95% CI, 1.00-1.65]; P < .001), loss of diagnosis (OR, 1.43 [95% CI, 1.12-1.74]; P < .001), and remission (OR, 1.62 [95% CI, 1.24-2.00]; P < .001) compared with the CPT group. Groups did not differ on other outcomes. Treatment dropout was higher in PE (254 participants [55.8%]) than in CPT (215 participants [46.6%]; P < .01). Three participants in the PE group and 1 participant in the CPT group were withdrawn from treatment, and 3 participants in each treatment dropped out owing to serious adverse events. Conclusions and Relevance: This randomized clinical trial found that although PE was statistically more effective than CPT, the difference was not clinically significant, and improvements in PTSD were meaningful in both treatment groups. These findings highlight the importance of shared decision-making to help patients understand the evidence and select their preferred treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT01928732.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553 · cited 1×
“2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.”
BackgroundDepression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
RUBIN, D. B. (1976) · Biometrika · doi:10.1093/biomet/63.3.581 · Cited by 9,925
Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment
THE WHOQOL GROUP (1998) · Psychological Medicine · doi:10.1017/s0033291798006667 · Cited by 7,933
Analysis of Incomplete Multivariate Data
Schafer, J. L. (1997) · doi:10.1201/9781439821862 · Cited by 6,012 · cited 1×
“2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.”
BackgroundBovin, M. J., Marx, B. P., Weathers, F. W., Gallagher, M. W., Rodriguez, P., Schnurr, P. P., & Keane, T. M. (2016) · Psychological Assessment · doi:10.1037/pas0000254 · Cited by 2,532
Self-citationWeathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018) · Psychological Assessment · doi:10.1037/pas0000486 · Cited by 1,799
Self-citationThe client satisfaction questionnaire
Attkisson, C. C., & Zwick, R. (1982) · Evaluation and Program Planning · doi:10.1016/0149-7189(82)90074-x · Cited by 1,743 · cited 1×
“2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.”
BackgroundCredibility of analogue therapy rationales
Borkovec, T. D., & Nau, S. D. (1972) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/0005-7916(72)90045-6 · Cited by 1,553 · cited 1×
“2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.”
BackgroundResick, P. A., Nishith, P., Weaver, T. L., Astin, M. C., & Feuer, C. A. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.70.4.867 · Cited by 1,294
Self-citationProlonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences - Therapist Guide
Foa, E., Hembree, E. A., Rothbaum, B. O., & Rauch, S. (2019) · doi:10.1093/med-psych/9780190926939.001.0001 · Cited by 412
Self-citationPsychometric properties of the Posttraumatic Diagnostic Scale for DSM–5 (PDS–5).
Foa, E. B., McLean, C. P., Zang, Y., Zhong, J., Powers, M. B., Kauffman, B. Y., Rauch, S., Porter, K., & Knowles, K. (2016) · Psychological Assessment · doi:10.1037/pas0000258 · Cited by 408
Self-citationFoa, E. B., McLean, C. P., Zang, Y., Rosenfield, D., Yadin, E., Yarvis, J. S., Mintz, J., Young-McCaughan, S., Borah, E. V., Dondanville, K. A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21242 · Cited by 357
Self-citationClient preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis
Lindhiem, O., Bennett, C. B., Trentacosta, C. J., & McLear, C. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.06.002 · Cited by 315
Karlin, B. E., & Cross, G. (2014) · American Psychologist · doi:10.1037/a0033888 · Cited by 283
A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update
Hamblen, J. L., Norman, S. B., Sonis, J. H., Phelps, A. J., Bisson, J. I., Nunes, V. D., Megnin-Viggars, O., Forbes, D., Riggs, D. S., & Schnurr, P. P. (2019) · Psychotherapy · doi:10.1037/pst0000231 · Cited by 264
Self-citationDevelopment and initial evaluation of the Brief Addiction Monitor (BAM)
Cacciola, J. S., Alterman, A. I., DePhilippis, D., Drapkin, M. L., Valadez, C., Fala, N. C., Oslin, D., & McKay, J. R. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.07.013 · Cited by 203 · cited 1×
“2 [21-80] years), with 455 participants randomized to PE (mean CAPS-5 score at baseline, 39.”
BackgroundKitchiner, N. J., Lewis, C., Roberts, N. P., & Bisson, J. I. (2019) · European Journal of Psychotraumatology · doi:10.1080/20008198.2019.1684226 · Cited by 113
Cited by
MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial
Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02565-4 · Cited by 455
Sloan, D. M., Marx, B. P., Acierno, R., Messina, M., Muzzy, W., Gallagher, M. W., Litwack, S., & Sloan, C. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.2810 · Cited by 80
Self-citationMDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Effects of MDMA-assisted therapy for PTSD on self-experience
van der Kolk, B. A., Wang, J. B., Yehuda, R., Bedrosian, L., Coker, A. R., Harrison, C., Mithoefer, M., Yazar-Klosinki, B., Emerson, A., & Doblin, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295926 · Cited by 55
Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
“These analyses underscore the importance of head-to-head interventions, as treatments that share similar effectiveness may benefit from treatment tailoring to minimize patient dropout (see: Schnurr et al. 2022).”
Metadata
- Authors
- Schnurr, P. P., Chard, K. M., Ruzek, J. I., Chow, B. K., Resick, P. A., Foa, E. B., Marx, B. P., Friedman, M. J., Bovin, M. J., Caudle, K. L., Castillo, D., Curry, K. T., Hollifield, M., Huang, G. D., Chee, C. L., Astin, M. C., Dickstein, B., Renner, K., Clancy, C. P., Collie, C., Maieritsch, K., Bailey, S., Thompson, K., Messina, M., Franklin, L., Lindley, S., Kattar, K., Luedtke, B., Romesser, J., McQuaid, J., Sylvers, P., Varkovitzky, R., Davis, L., MacVicar, D., & Shih, M.-C.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2022-01-19
- Volume
- 5
- Issue
- 1
- Pages
- e2136921
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W4205735310
- Cited by
- 185
- References
- 19
- FWCI
- 31.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.